Search
Climb Bio Inc
CLYMAdd to Watchlist
11.890USD
-0.630-5.03%
Close 09-23 16:00（ET）
680.82MMarket Cap
LossP/E TTM
Climb Bio Inc (CLYM) Stock Price Target & Forecast
Analyst Rating
Based on 15 analysts giving stock ratings to Climb Bio Inc in the past month.
Strong Buy
8 Strong Buy
7 Buy
0 Hold
0 Sell
0 Strong Sell
Target Price
27.857USD+122.50%
CLYM Analyst Recommendation Trends
In the current month, CLYM has received 7 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. CLYM average Analyst price target in the last month is 27.857.
2026-09
2026-08
2026-07
2026-06
2026-05
2026-04
2026-03
2026-02
8
8
8
7
7
7
5
5
7
7
7
7
6
5
3
2
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
15
15
15
14
13
12
8
7
Financial Forecasting
Based on analysts' estimates, CLYM EPS is projected to reach -0.199 in FY2026Q3, following reported EPS of -0.177 in FY2026Q2. Track earnings expectations against reported figures to see how profitability is evolving.
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FY2025Q4
FY2026Q1
FY2026Q2
FY2026Q3
FY2026Q4
Forecast
-0.20
-0.27
-0.21
-0.20
-0.21
Actual
-0.26
-0.20
-0.18
--
--
Surprise
-30.39%
+24.56%
+17.01%
--
--
FAQs
What is Climb Bio Inc's price target?
Analysts forecast that Climb Bio Inc's price target is USD 9.00, with the highest forecast at USD 10.00 and the lowest forecast at USD 8.00.
How have Climb Bio IncCLYM's recent earnings per share performed?
The market expectation was USD -0.18, while Climb Bio IncCLYM's earnings per share (EPS) for the previous quarter was USD -0.20. EPS for the next quarter is expected at USD -0.20.
What is the analyst rating for Climb Bio Inc?
Based on the ratings of Climb Bio Inc's stock from 15 analysts, most analysts support a STRONG BUY trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as STRONG BUY. Please note that this is not trading advice. You still need to conduct your own analysis.